Infections and Infectious Diseases | Phase II Developments | FRANCE

Deinove SAS

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

DNV3837 Antibiotic Candidate: the Phase II Trial Continues in the US

Lead Product(s): Oxaquin

Therapeutic Area: Infections and Infectious Diseases Product Name: DNV3837

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 15, 2020

Details:

DNV3837 targets the treatment of Clostridioides difficile gastrointestinal infections (CDI), a pathogen classified as urgent threat by the U.S. Centers for Disease Control and Prevention (CDC).

Osivax

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

Osivax Receives Over EUR 30M in Public Funding to Support Development of Universal Coronavirus & Influenza Vaccines

Lead Product(s): OVX836

Therapeutic Area: Infections and Infectious Diseases Product Name: OVX836

Highest Development Status: Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: European Innovation Council

Deal Size: $34.0 million Upfront Cash: Undisclosed

Deal Type: Funding July 08, 2020

Details:

The grant willsupport the completion of the Company’s Phase 2a immunogenicity clinical trial for OVX836, its lead universal flu vaccine candidate and the early discovery phase for its universal coronavirus vaccine program.

Valneva SE

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

Valneva Announces HSR Clearance for Lyme Vaccine Collaboration with Pfizer

Lead Product(s): VLA15

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Pfizer Inc

Deal Size: $308.0 million Upfront Cash: $130.0 million

Deal Type: Agreement June 08, 2020

Details:

Valneva and Pfizer will work closely together throughout the development of VLA15. The agreement was signed at the end of April 2020 to develop and commercialize Valneva’s Lyme disease vaccine candidate VLA15, which is currently in Phase 2 clinical studies.

Valneva SE

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

Valneva and Pfizer Announce Collaboration to Co-Develop and Commercialize Lyme Disease Vaccine, VLA15

Lead Product(s): VLA15

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Pfizer Inc

Deal Size: $308.0 million Upfront Cash: $130.0 million

Deal Type: Collaboration April 30, 2020

Details:

Valneva and Pfizer will work closely together to develop and commercialize Valneva’s Lyme disease vaccine candidate VLA15, which is currently in Phase 2 clinical studies.

Innate Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

France France

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

First Patient Dosed in Avdoralimab Phase Ii Clinical Trial in Covid-19 Patients with Severe Pneumonia

Lead Product(s): Avdoralimab

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 28, 2020

Details:

First patient was dosed in a randomized, double-blind Phase II clinical trial, evaluating the safety and efficacy of its anti-C5aR antibody, avdoralimab (IPH5401), in COVID-19 patients.

Valneva SE

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

Valneva Reports Positive End-of-Phase 2 Chikungunya Meeting with the U.S. FDA; Sets Stage for Phase 3 Study

Lead Product(s): VLA1553

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 25, 2020

Details:

The main Phase 3 pivotal trial will be, subject to detailed protocol review, a double-blinded, placebo-controlled, multi-center study in approximately 4,000 healthy adults.

DaVolterra

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

Da Volterra Reports Positive Top-line Results from DAV132 Study

Lead Product(s): DAV132

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 11, 2020

Details:

Primary endpoint met: DAV132 was safe for use in hospitalized patients with several comorbidities and concomitant medications.

Valneva SE

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

Valneva Announces New $85 Million Financing Arrangement

Lead Product(s): VLA15

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Deerfield Management Company

Deal Size: $85.0 million Upfront Cash: $60.0 million

Deal Type: Financing February 03, 2020

Details:

Valneva will use funds to further advance its leading Lyme and chikungunya development programs and to repay existing debt.

Deinove SAS

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

Enrolment of first patient in Phase II trial testing DNV3837 in Clostridioides difficile infections

Lead Product(s): DNV3837

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 27, 2020

Details:

The Phase II clinical trial aims to evaluate the efficacy, safety and pharmacokinetics of DNV3837 in patients with Clostridioides difficile gastrointestinal infection (CDI).

Find

Find Drugs for Infections and Infectious Diseases in Phase II Clinical Development in FRANCE

France

Product Type

Companies

Deinove SAS

DNV3837 Antibiotic Candidate: the Phase II Trial Continues in the US

Osivax

Osivax Receives Over EUR 30M in Public Funding to Support Development of Universal Coronavirus & Influenza Vaccines

Valneva SE

Valneva Announces HSR Clearance for Lyme Vaccine Collaboration with Pfizer

Valneva SE

Valneva and Pfizer Announce Collaboration to Co-Develop and Commercialize Lyme Disease Vaccine, VLA15

Innate Pharma

First Patient Dosed in Avdoralimab Phase Ii Clinical Trial in Covid-19 Patients with Severe Pneumonia

Valneva SE

Valneva Reports Positive End-of-Phase 2 Chikungunya Meeting with the U.S. FDA; Sets Stage for Phase 3 Study

DaVolterra

Da Volterra Reports Positive Top-line Results from DAV132 Study

Valneva SE

Valneva Announces New $85 Million Financing Arrangement

Deinove SAS

Enrolment of first patient in Phase II trial testing DNV3837 in Clostridioides difficile infections